Title:
COMPOSITIONS AND METHODS FOR GENOMIC EDITING
Document Type and Number:
WIPO Patent Application WO/2023/245109
Kind Code:
A3
Abstract:
Compositions and methods for ex vivo genomic editing using Neisseria meningitidis (Nme) CRISPR/Cas9 systems are disclosed. The present disclosure provides for engineered cells comprising a genetical modification for use e.g., in adoptive cell transfer therapies.
More Like This:
| JP2011501741 | TAZ / WWTR1 for cancer diagnosis and treatment |
| WO/2011/111874 | CELL MEMBRANE-PERMEATING DUMBBELL-TYPE RNA AND METHOD FOR PRODUCING THE SAME |
| JP2022552249 | Modulator of PNPLA3 expression |
Inventors:
OLIVEIRA RUAN (US)
CHOI SUNG HEE (US)
LIU BIAO (US)
BARVE RADHIKA (US)
CHOI SUNG HEE (US)
LIU BIAO (US)
BARVE RADHIKA (US)
Application Number:
PCT/US2023/068499
Publication Date:
February 01, 2024
Filing Date:
June 15, 2023
Export Citation:
Assignee:
INTELLIA THERAPEUTICS INC (US)
International Classes:
C12N15/113; C12N5/0783; C12N9/22; C12N9/78
Domestic Patent References:
| WO2022115472A1 | 2022-06-02 | |||
| WO2016201047A1 | 2016-12-15 |
Foreign References:
| EP3754018A1 | 2020-12-23 | |||
| CN112481310A | 2021-03-12 | |||
| CN109456942A | 2019-03-12 |
Other References:
KOJIMA TAKU ET AL: "Development of HLA-modified induced pluripotent stem cell-derived dendritic cells for a novel cancer immunotherapy", JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, MEDICINE, AND PATHOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 34, no. 5, 24 March 2022 (2022-03-24), pages 643 - 652, XP087142663, ISSN: 2212-5558, [retrieved on 20220324], DOI: 10.1016/J.AJOMS.2022.02.002
Attorney, Agent or Firm:
BAUR, Amelia Feulner et al. (US)
Download PDF: